Reiter's syndrome. A review of current status and a hypothesis regarding its pathogenesis.
D000963:Antimetabolites / Q000627:therapeutic use; D016918:Arthritis, Reactive / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D002689:Chlamydia / Q000302:isolation & purification; D002690:Chlamydia Infections / Q000150:complications; D004405:Dysentery, Bacillary / Q000150:complications; D005260:Female; D006511:Hepatitis B Antigens / Q000032:analysis; D006566:Herpesviridae Infections / Q000150:complications; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007958:Leukocyte Count; D008297:Male; D009174:Mycoplasma / Q000302:isolation & purification; D009175:Mycoplasma Infections / Q000150:complications; D010653:Phenylbutazone / Q000627:therapeutic use; D011379:Prognosis; D012459:Salicylates / Q000627:therapeutic use; D012480:Salmonella Infections / Q000150:complications; D012749:Sexually Transmitted Diseases / Q000175:diagnosis; D012760:Shigella / Q000302:isolation & purification; D013582:Synovial Fluid / Q000032:analysis
D000963:Antimetabolites; D006511:Hepatitis B Antigens; D012459:Salicylates; D010653:Phenylbutazone; D007213:Indomethacin